Skip to main content
. 2023 Jun 9;24(12):9939. doi: 10.3390/ijms24129939

Table 1.

MSC-therapy-related adverse events described in the clinical trials.

Reference Follow-Up (Years) AE Number of Patients Percentage of N Duration of AE Intensity of AE
[19] 1 Joint pain 6 50% 1–6 days Mild
Joint inflammation 3 25% NA Mild
Back pain 3 25% NA Mild
Tendonitis 1 8% NA Mild
[20] 1 Joint swelling 2 13% NA Mild
Joint lock 1 6% NA Mild
Back pain 3 20% 2–3 days Mild
Arthralgia 8 53% 2–3 days Mild
[22] 1–2 Joint pain 2 15% 1 day Mild
Joint swelling 1 8% 2 days Mild
[25] 1 Joint pain 4 33% 2–4 weeks Mild
Joint swelling 2 17% 4 weeks Mild
[30] 0.5 Joint pain and swelling 1 2% 2 days Mild
[32] 0.5 Joint swelling 3 12% 6 months Moderate
[33] 1 Joint swelling 2 8% 12 months Moderate
[40] 0.5 Joint swelling 5 28% NA Mild
[41] 0.5 Arthralgia 6 50% 6 months Moderate
Joint swelling 2 17% 6 months Moderate
[42] 1 Joint pain and swelling 2 7% 4 weeks Mild
Discomfort and bruising 18 60% NA Mild
[43] 0.5–1 Joint swelling 1 3% NA Mild
[44] 2 Joint pain 4 11% NA Mild
Joint swelling 15 44% NA Mild
Joint edema and cramps 1 3% NA Mild
[45] 1 Joint pain and swelling 19 36% 7 days Mild
[46] 2 Joint pain and swelling 5 17% NA Mild
Skin erythema 2 7% NA Mild
[28] 1 Joint pain and swelling 8 53% 7 days Mild
[29] 1 Joint pain and swelling 4 7% NA Mild
Arthralgia 2 3% NA Mild
[47] 1 Joint pain 18 82% 3 weeks Moderate
Joint swelling 3 14% 3 weeks Mild
Joint edema 10 45% 3 weeks Mild
[51] 1 Joint pain 9 16% NA Mild
Joint swelling 6 10% NA Mild
Arthralgia 8 14% NA Mild
Joint stiffness 2 3% NA Mild
[54] 7 Arthralgia 2 30% NA Mild
Back pain 1 14% NA Mild
Increased infection susceptibility 1 14% NA Mild
[56] 0.5 Joint pain and swelling 4 20% 3 days Mild
[37] 1.5 Joint swelling 8 23% NA Mild
Arthralgia 13 37% NA Mild
Crepitations 5 14% NA Mild

NA: not available.